Outlook for 2010

Published on 26 October 2010

Net sales will be higher than in 2009.

Marketing expenditure will be higher due to the increased number of product launches and expansion of operations into Southern Europe. Research expenditure and the costs of patent litigation in the United States will be lower than in 2009.

Operating profit excluding non-recurring items will be clearly higher than in 2009.

The Group’s capital expenditure will be about EUR 40 million excluding substantial corporate or product acquisitions.

Published on 10 August 2010

Net sales will be higher than in 2009.

Marketing expenditure will be higher due to the increased number of product launches and expansion of operations into Southern Europe. Research expenditure and the costs of patent litigation in the United States will be lower than in 2009.

Operating profit excluding non-recurring items will be higher than in 2009.

The Group’s capital expenditure will be about EUR 40 million excluding substantial corporate or product acquisitions.

The second paragraph of Outlook for 2010 was previously:
Marketing expenditure will be higher due to the increased number of product launches and expansion of operations to Southern Europe. Research expenditure will be lower than in 2009. The costs of ongoing patent litigation in the United States are expected to be lower than in 2009.

Published on 14 June 2010

Orion upgrades full-year outlook for 2010

The positive earnings development reported by the Orion Group for the first quarter of 2010 has continued showing similar performance also in the second quarter. Despite the increasingly tightened situation on the market, sales have shown continued positive development whereas costs have remained at the previous year's level. In the light of the current development, the Board of Directors of Orion Corporation has decided to change the full-year outlook estimate for 2010 provided in the Interim Report 1–3/2010 and published on 27 April 2010. The basis for the outlook remains the same as that for the outlook provided in the Interim Report published on 27 April 2010.

Net sales will be higher than in 2009.

Marketing expenditure will be higher due to the increased number of product launches and the expansion of operations to Southern Europe. Research expenditure will be lower than in 2009. The costs of ongoing patent litigation in the United States are expected to be lower than in 2009.

Operating profit excluding non-recurring items will be higher than in 2009.

The Group’s capital expenditure will be about EUR 40 million excluding substantial corporate or product acquisitions.

Published on 27 April 2010

Net sales will be slightly higher than in 2009.

Marketing expenditure will be higher due to the increased number of product launches and the expansion of operations to Southern Europe. Research expenditure will be slightly lower than in 2009. The costs of ongoing patent litigation in the United States are expected to be lower than in 2009.

Operating profit excluding non-recurring items will be slightly higher than in 2009.

The Group’s capital expenditure will be about EUR 40 million excluding substantial corporate or product acquisitions.

Published on 9 February 2010

Net sales will be slightly higher than in 2009.

Marketing expenditure will be higher due to the increased number of product launches and increased costs of sales and marketing related to Simdax. Research expenditure will be slightly lower than in 2009. The costs of ongoing patent litigation in the United States are also expected to be similar to 2009.

Operating profit excluding non-recurring items will be slightly higher than in 2009.

The Group’s capital expenditure will be about EUR 40 million excluding substantial corporate or product acquisitions.